Search Videos by Topic or Participant
Browse by Series:

Utility of MRD in Mantle Cell Lymphoma

Panelists: Myron S. Czuczman, MD, Roswell Park; John C. Byrd, MD, Ohio State;Richard Furman, MD, Weill Cornell; Thomas J. Kipps, MD, UCSD; Shuo
Published: Friday, May 15, 2015
For High-Definition, Click
A number of treatment options are currently available for mantle cell lymphoma (MCL), explains John C. Byrd, MD, and Myron Czuczman, MD. There is controversy regarding the frontline administration of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) in the frontline setting. Richard Furman, MD, describes a trial that added bortezomib to R-CHOP and produced impressive results, suggesting that long-term remissions can be achieved without using the more toxic regimens.

Minimal residual disease (MRD) could be utilized as a prognostic factor in MCL, suggests Shuo Ma, MD, PhD. The German group analyzed the effect of MRD in terms of prognosis for patients with MCL <65 years who were treated with immuno-chemotherapy followed by autologous stem cell transplantation for patients, and patients with MCL >65 years who were treated with rituximab or interferon maintenance. Based on these analyses, MRD-negativity appears to be the single most important prognostic factor, even more than Mantle Cell Lymphoma International Prognostic Index (MIPI) scores.


Slider Left
Slider Right
For High-Definition, Click
A number of treatment options are currently available for mantle cell lymphoma (MCL), explains John C. Byrd, MD, and Myron Czuczman, MD. There is controversy regarding the frontline administration of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) in the frontline setting. Richard Furman, MD, describes a trial that added bortezomib to R-CHOP and produced impressive results, suggesting that long-term remissions can be achieved without using the more toxic regimens.

Minimal residual disease (MRD) could be utilized as a prognostic factor in MCL, suggests Shuo Ma, MD, PhD. The German group analyzed the effect of MRD in terms of prognosis for patients with MCL <65 years who were treated with immuno-chemotherapy followed by autologous stem cell transplantation for patients, and patients with MCL >65 years who were treated with rituximab or interferon maintenance. Based on these analyses, MRD-negativity appears to be the single most important prognostic factor, even more than Mantle Cell Lymphoma International Prognostic Index (MIPI) scores.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x